These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 4046862)

  • 1. Membrane systems: practical applications.
    Smith KL
    Methods Enzymol; 1985; 112():504-20. PubMed ID: 4046862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable controlled release systems.
    Langer R
    Pharmacol Ther; 1983; 21(1):35-51. PubMed ID: 6353438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microsealed drug delivery systems: fabrications and performance.
    Chien YW
    Methods Enzymol; 1985; 112():461-70. PubMed ID: 3930920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Steroid intra-uterine contraception: progesterone-releasing devices. II. Insertion, clinical problems and contraceptive dependability].
    Custo GM; Cosmi EV
    Patol Clin Ostet Ginecol; 1984; 12(4):331-43. PubMed ID: 12340352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion of progestogens through Silastic rubber implants.
    Lifchez AS; Scommegna A
    Fertil Steril; 1970 May; 21(5):426-30. PubMed ID: 4101385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of an estriol-releasing intrauterine device.
    Baker RW; Tuttle ME; Lonsdale HK; Ayres JW
    J Pharm Sci; 1979 Jan; 68(1):20-6. PubMed ID: 758458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progestasert: a uterine therapeutic system for long-term contraception: I. Philosophy and clinical efficacy.
    Pharriss BB; Erickson R; Bashaw J; Hoff S; Place VA; Zaffaroni A
    Fertil Steril; 1974 Nov; 25(11):915-21. PubMed ID: 4426403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A risk-benefit assessment of the levonorgestrel-releasing intrauterine system.
    Sturridge F; Guillebaud J
    Drug Saf; 1996 Dec; 15(6):430-40. PubMed ID: 8968696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rates and outcomes of planned pregnancy after use of Norplant capsules, Norplant II rods, or levonorgestrel-releasing or copper TCu 380Ag intrauterine contraceptive devices.
    Sivin I; Stern J; Diaz S; Pavéz M; Alvarez F; Brache V; Mishell DR; Lacarra M; McCarthy T; Holma P
    Am J Obstet Gynecol; 1992 Apr; 166(4):1208-13. PubMed ID: 1566771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversible contraception for the woman over 35 years of age.
    Archer DF
    Curr Opin Obstet Gynecol; 1992 Dec; 4(6):891-6. PubMed ID: 1450355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poly(ortho ester) biodegradable polymer systems.
    Heller J; Himmelstein KJ
    Methods Enzymol; 1985; 112():422-36. PubMed ID: 3930918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a progesterone-releasing intrauterine contraceptive device on endometrial blood vessels: a morphometric study.
    Shaw ST; Macaulay LK; Aznar R; González-Angulo A; Roy S
    Am J Obstet Gynecol; 1981 Dec; 141(7):821-7. PubMed ID: 7315908
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Controlled drug release from polymeric delivery devices IV: in vitro--in vivo correlation of subcutaneous release of norgestomet from hydrophilic implants.
    Chien YW; Lau EP
    J Pharm Sci; 1976 Apr; 65(4):488-92. PubMed ID: 1271244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical study of a progesterone-releasing intrauterine contraceptive device.
    Brenner PF; Cooper DL; Mishell DR
    Am J Obstet Gynecol; 1975 Mar; 121(5):704-6. PubMed ID: 1115173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transdermal delivery of steroids.
    Sitruk-Ware R
    Contraception; 1989 Jan; 39(1):1-20. PubMed ID: 2642780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The end of IUD marketing in the United States: what does it mean for American women?].
    Forrest JD
    Contracept Fertil Sex (Paris); 1987 Mar; 15(3):291-300. PubMed ID: 12341479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of T-shaped progesterone-releasing system on contraceptive efficacy and menstrual cycle regularity in Japanese monkeys.
    Oshima K; Hayashi M; Kato J
    Fertil Steril; 1976 May; 27(5):582-7. PubMed ID: 819310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone-releasing vaginal rings for use in postpartum contraception. I. In vitro release rates of progesterone from core-loaded rings.
    Matlin SA; Belenguer A; Hall PE
    Contraception; 1992 Apr; 45(4):329-41. PubMed ID: 1516365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical considerations of transdermal nitroglycerin delivery: the various approaches.
    Chien YW
    Am Heart J; 1984 Jul; 108(1):207-16. PubMed ID: 6428207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.